XADAGO (safinamide) tablets

XADAGO is a brand-name prescription drug that’s FDA-approved to treat levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes , and ulcerative colitis. XADAGO (safinamide) tablets, for oral use Initial U.S. Approval: 2017

Home | (safinamide) tablets

XADAGO (safinamide) tablets Price In India and Overseas
XADAGO (safinamide) tablets

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Overseas Patient/ Export inquires.

Call / WhatsApp Number
+91 9643240915 (Mr. Yashpal Singh)
+91 9289711087 (Ms. Sana Sadyar)

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

XADAGO (safinamide) tablets

Safinamide is used to treat idiopathic Parkinson's disease as add-on for people taking a stable dose of levodopa (L-dopa) alone or in combination with other Parkinson drugs.

XADAGO is a type of prescription medicine known as monoamine oxidase type B (MAO-B) inhibitor used with levodopa and carbidopa to treat adults with Parkinson’s disease (PD) who are having “off” episodes. Active ingredient: safinamide mesylate Inactive ingredients: microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol 6000, iron oxide (red), potassium aluminum silicate, and titanium dioxide.

Safinamide is used to treat idiopathic Parkinson’s disease as add-on for people taking a stable dose of levodopa (L-dopa) alone or in combination with other Parkinson drugs, to help with “off” episodes when levodopa stops working. Safinamide (INN; brand name Xadago) xinafact 50 mg is a drug used as an add-on treatment for Parkinson’s disease with “off” episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B. It was approved in the European Union in February 2015, in the United States in March 2017, and in Canada in January 2019.

Drug (Brand / Generic): XADAGO / safinamide tablets
Current Indications: Parkinson’s disease (PD)
Marketed by:: US WorldMeds, LLC,
Approval Date: 2017

Available as (Form & Strength): Tablets: 50 mg and 100 mg

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.